MA43404A - Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques - Google Patents

Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Info

Publication number
MA43404A
MA43404A MA043404A MA43404A MA43404A MA 43404 A MA43404 A MA 43404A MA 043404 A MA043404 A MA 043404A MA 43404 A MA43404 A MA 43404A MA 43404 A MA43404 A MA 43404A
Authority
MA
Morocco
Prior art keywords
expression
compositions
treatment
conditions
methods
Prior art date
Application number
MA043404A
Other languages
English (en)
Inventor
Amit N Patel
Dimki S Patel
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of MA43404A publication Critical patent/MA43404A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA043404A 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques MA43404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254139P 2015-11-11 2015-11-11

Publications (1)

Publication Number Publication Date
MA43404A true MA43404A (fr) 2018-10-17

Family

ID=57543150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043404A MA43404A (fr) 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Country Status (14)

Country Link
US (3) US11154622B2 (fr)
EP (1) EP3387010A1 (fr)
JP (1) JP6976244B2 (fr)
KR (1) KR20180069081A (fr)
CN (1) CN108713025A (fr)
AU (1) AU2016353342B2 (fr)
BR (1) BR112018009645A2 (fr)
CA (1) CA3004742A1 (fr)
HK (1) HK1259137A1 (fr)
MA (1) MA43404A (fr)
MX (1) MX2018005886A (fr)
RU (1) RU2758489C2 (fr)
SG (1) SG11201803934YA (fr)
WO (1) WO2017083750A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110462040A (zh) 2017-01-10 2019-11-15 英特拉克森公司 通过新基因开关表达系统调节多肽的表达
EP3690054A4 (fr) * 2017-09-29 2021-07-28 BethphaGen Inc. Composition pharmaceutique pour la prévention ou le traitement d'une insuffisance cardiaque
KR20200128703A (ko) 2018-03-06 2020-11-16 프레시전 인코포레이티드 B형 간염 백신 및 이의 용도
WO2019218091A1 (fr) * 2018-05-18 2019-11-21 UNIVERSITé LAVAL Vecteurs pour l'immunisation par adn
MX2020012649A (es) * 2018-05-25 2021-07-02 The Wistar Inst Neoantígenos especificos de tumor y métodos de uso de estos.
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
SG11202110360TA (en) * 2019-03-29 2021-10-28 Abiomed Inc Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy
US20210290753A1 (en) * 2019-05-21 2021-09-23 UNIVERSITé LAVAL Crimean-congo hemorrhagic fever virus immunogenic compositions
AU2020350140A1 (en) * 2019-09-20 2022-03-31 Ucl Business Ltd Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy
AU2021320902A1 (en) 2020-08-07 2023-04-06 Spacecraft Seven, Llc Plakophilin-2 (PKP2) gene therapy using AAV vector
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2023019272A1 (fr) * 2021-08-12 2023-02-16 Temple University Of The Commonwealth System Of Higher Education Administration rétrograde veineuse ou sinusale coronaire d'agents thérapeutiques
WO2023232984A1 (fr) * 2022-06-02 2023-12-07 Patrick Most Protéine s100a1 destinée à être utilisée dans le traitement et la prévention d'une prolongation d'infarctus

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
MXPA02009157A (es) 2000-03-22 2004-04-05 Rohm & Haas Nuevo sistema de expresion genetica inducible a base del receptor de ecdisona.
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
WO2002066615A2 (fr) 2001-02-20 2002-08-29 Rheogene, Inc. Nouveaux recepteurs a mutant de substitution et utilisation de ceux-ci dans un systeme d'expression de gene inductible fonde sur un recepteur nucleaire
ES2392508T3 (es) 2001-02-20 2012-12-11 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
MXPA04002808A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
WO2003027289A1 (fr) 2001-09-26 2003-04-03 Rheo Gene Holdings, Inc. Acides nucleiques du recepteur a l'ecdysone de la cicadelle, polypeptides, et utilisation de ceux-ci
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
EP2043662B1 (fr) 2006-07-26 2015-09-09 Intrexon Corporation Methodes et compositions de traitement de maladie
WO2008088870A1 (fr) 2007-01-19 2008-07-24 Progressive Gaming International Corporation Système d'identification de surveillance de table, étiquetage de pari et cartographie de coordonnées
EP3357904B1 (fr) 2007-05-29 2022-07-06 Precigen, Inc. Ligands diacylhydrazine chiraux destinés à moduler l'expression de gènes exogènes par le biais d'un complexe récepteur de l'ecdysone
RU2499599C2 (ru) 2007-09-28 2013-11-27 Интрексон Корпорейшн Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
HUE035406T2 (en) 2007-10-08 2018-05-02 Intrexon Corp Modified dendritic cells and uses for cancer treatment
WO2009114702A2 (fr) * 2008-03-14 2009-09-17 Humanzyme Limited Production recombinante de protéines humaines authentiques utilisant des systèmes d’expression de cellules humaines
CA2739902A1 (fr) 2008-10-08 2010-04-15 Intrexon Corporation Cellules modifiees exprimant des immuno-modulateurs multiples et leurs utilisations
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
CN103534355A (zh) 2011-03-04 2014-01-22 英特瑞克斯顿股份有限公司 条件性表达蛋白质的载体
EP2919808B1 (fr) * 2012-11-16 2020-07-29 United Biomedical, Inc. Vaccin d'urgence à base d'un peptide synthétique contre la fièvre aphteuse (fmd)
WO2014089121A2 (fr) * 2012-12-03 2014-06-12 Thomas Ichim Administration rétrograde de cellules et d'acides nucléiques pour le traitement de maladies cardiovasculaires
EP2968608A4 (fr) 2013-03-15 2016-10-26 Cleveland Clinic Foundation Administration rétrograde de sdf-1 pour le traitement d'un infarctus du myocarde
WO2016187585A1 (fr) 2015-05-20 2016-11-24 Viventia Bio Inc. Lieur désimmunisé et méthodes d'utilisation
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用

Also Published As

Publication number Publication date
US20220072159A1 (en) 2022-03-10
JP2018536405A (ja) 2018-12-13
RU2018117674A3 (fr) 2020-04-20
HK1259137A1 (zh) 2019-11-29
CN108713025A (zh) 2018-10-26
US20180360992A1 (en) 2018-12-20
AU2016353342A1 (en) 2018-05-24
AU2016353342B2 (en) 2021-04-01
US11154622B2 (en) 2021-10-26
JP6976244B2 (ja) 2021-12-08
WO2017083750A1 (fr) 2017-05-18
SG11201803934YA (en) 2018-06-28
KR20180069081A (ko) 2018-06-22
RU2758489C2 (ru) 2021-10-28
EP3387010A1 (fr) 2018-10-17
BR112018009645A2 (pt) 2018-11-13
US20240148908A1 (en) 2024-05-09
RU2018117674A (ru) 2019-12-13
CA3004742A1 (fr) 2017-05-18
MX2018005886A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
MA43404A (fr) Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL264025A (en) Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
SG11202112652RA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
WO2016057658A8 (fr) Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
FR3020951B1 (fr) Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique.
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
MA52579A (fr) Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases